These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 26334891)

  • 1. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
    Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
    Ueno M; Okusaka T; Omuro Y; Isayama H; Fukutomi A; Ikeda M; Mizuno N; Fukuzawa K; Furukawa M; Iguchi H; Sugimori K; Furuse J; Shimada K; Ioka T; Nakamori S; Baba H; Komatsu Y; Takeuchi M; Hyodo I; Boku N
    Ann Oncol; 2016 Mar; 27(3):502-8. PubMed ID: 26681680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
    Jin SF; Fan ZK; Pan L; Jin LM
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
    Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
    BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
    Liu Y; Huang QK; Hong WD; Wu JM; Sun XC
    Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.
    Zhong S; Qie S; Yang L; Yan Q; Ge L; Wang Z
    Medicine (Baltimore); 2017 Jul; 96(30):e7611. PubMed ID: 28746215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
    Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H
    J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
    Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
    Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
    Suzuki S; Ozaki Y; Saida S; Kaji S; Koike N; Harada N; Hayashi T; Suzuki M
    Hepatogastroenterology; 2013 Jun; 60(124):916-20. PubMed ID: 23478143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
    Xu Y; Guo X; Fan Y; Wang D; Wu W; Wu L; Liu T; Xu B; Feng Y; Wang Y; Lou W; Zhou Y
    Jpn J Clin Oncol; 2018 Jun; 48(6):535-541. PubMed ID: 29718363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
    Imaoka H; Kou T; Tanaka M; Egawa S; Mizuno N; Hijioka S; Hara K; Yazumi S; Shimizu Y; Yamao K
    Eur J Cancer; 2016 Feb; 54():96-103. PubMed ID: 26741729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.
    Sudo K; Ishihara T; Hirata N; Ozawa F; Ohshima T; Azemoto R; Shimura K; Nihei T; Nishino T; Nakagawa A; Nakamura K; Hara T; Tada M; Mikata R; Tawada K; Yokosuka O; Nakaji S; Yamaguchi T
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):389-96. PubMed ID: 24322377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
    Ozaka M; Matsumura Y; Ishii H; Omuro Y; Itoi T; Mouri H; Hanada K; Kimura Y; Maetani I; Okabe Y; Tani M; Ikeda T; Hijioka S; Watanabe R; Ohoka S; Hirose Y; Suyama M; Egawa N; Sofuni A; Ikari T; Nakajima T
    Cancer Chemother Pharmacol; 2012 May; 69(5):1197-204. PubMed ID: 22249272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine plus S-1 for metastatic pancreatic cancer.
    Zhu H; Yi C; Zhao Y; Gou H
    Medicine (Baltimore); 2018 Oct; 97(41):e12836. PubMed ID: 30313120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
    Umemura A; Nitta H; Sasaki A; Takahara T; Hasegawa Y; Wakabayashi G
    Hepatogastroenterology; 2014 May; 61(131):814-20. PubMed ID: 26176079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis.
    Lu S; Zhang Y; Zhou X; Zhou D; Yang Q; Ju B; Zhao X; Hu Z; Xie H; Zhou L; Zheng S; Wang W
    Sci Rep; 2016 Nov; 6():36944. PubMed ID: 27833144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.